目的探讨小儿支气管哮喘病采用匹多莫德口服液治疗的临床疗效。方法 98例小儿支气管哮喘病患儿,随机分为治疗组和对照组;对照组(50例)采用常规治疗方案,治疗组(48例)在常规治疗方法基础上施加匹多莫德口服液治疗方案,并观察两组治疗临床疗效、免疫功能免疫球蛋白A(Ig A)、免疫球蛋白M(Ig M)及免疫球蛋白G(Ig G)指标情况。结果治疗组总有效率93.75%,对照组总有效率80.00%,治疗组明显优于对照组,差异具有统计学意义(P<0.05)。治疗后治疗组Ig A、Ig M及Ig G均明显高于对照组,差异均具有统计学意义(P<0.01,t=3.08;t=2.05;t=11.45)。结论在常规治疗的基础上施加匹多莫德口服液治疗小儿支气管哮喘性疾病临床疗效显著,明显提高机体抗体水平、安全性好。 Objective To investigate the clinical efficacy of pidotimod oral solution in children with bronchial asthma. Methods A total of 98 infants with bronchial asthma were randomly divided into treatment group and control group. The control group (50 cases) received routine treatment. The treatment group (48 cases) received Pidotimod oral solution on the basis of conventional treatment The clinical efficacy, immunoglobulin A (Ig A), immunoglobulin M (Ig M) and immunoglobulin G (Ig G) indicators of the two groups were observed. Results The total effective rate was 93.75% in the treatment group and 80.00% in the control group, which was significantly better in the treatment group than in the control group. The difference was statistically significant (P <0.05). After treatment, the Ig A, Ig M and Ig G of the treatment group were significantly higher than those of the control group, the differences were statistically significant (P <0.01, t = 3.08; t = 2.05; t = 11.45). Conclusion The application of pidotimod oral solution on children with bronchial asthma based on routine treatment has obvious clinical curative effect, obviously raising body antibody level and good safety.